South Korea · Delayed Price · Currency is KRW Cell Biotech Statistics
Total Valuation
Cell Biotech has a market cap or net worth of KRW 96.91 billion. The enterprise value is 4.27 billion.
| Market Cap | 96.91B |
| Enterprise Value | 4.27B |
Important Dates
The next estimated earnings date is Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Cell Biotech has 6.84 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 6.84M |
| Shares Outstanding | 6.84M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 35.37% |
| Owned by Institutions (%) | 8.75% |
| Float | 4.42M |
Valuation Ratios
The trailing PE ratio is 9.57.
| PE Ratio | 9.57 |
| Forward PE | n/a |
| PS Ratio | 1.82 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | 12.11 |
| P/OCF Ratio | 8.72 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 0.37, with an EV/FCF ratio of 0.53.
| EV / Earnings | 0.42 |
| EV / Sales | 0.08 |
| EV / EBITDA | 0.37 |
| EV / EBIT | 0.54 |
| EV / FCF | 0.53 |
Financial Position
The company has a current ratio of 21.34, with a Debt / Equity ratio of 0.00.
| Current Ratio | 21.34 |
| Quick Ratio | 20.19 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.05 |
| Interest Coverage | 242.84 |
Financial Efficiency
Return on equity (ROE) is 7.92% and return on invested capital (ROIC) is 18.32%.
| Return on Equity (ROE) | 7.92% |
| Return on Assets (ROA) | 3.71% |
| Return on Invested Capital (ROIC) | 18.32% |
| Return on Capital Employed (ROCE) | 6.01% |
| Weighted Average Cost of Capital (WACC) | 6.21% |
| Revenue Per Employee | 526.00M |
| Profits Per Employee | 100.25M |
| Employee Count | 101 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 3.35 |
Taxes
In the past 12 months, Cell Biotech has paid 1.13 billion in taxes.
| Income Tax | 1.13B |
| Effective Tax Rate | 10.03% |
Stock Price Statistics
The stock price has increased by +12.11% in the last 52 weeks. The beta is 0.36, so Cell Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | +12.11% |
| 50-Day Moving Average | 13,901.00 |
| 200-Day Moving Average | 13,176.70 |
| Relative Strength Index (RSI) | 50.21 |
| Average Volume (20 Days) | 15,170 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cell Biotech had revenue of KRW 53.13 billion and earned 10.13 billion in profits. Earnings per share was 1,479.00.
| Revenue | 53.13B |
| Gross Profit | 38.36B |
| Operating Income | 7.91B |
| Pretax Income | 11.25B |
| Net Income | 10.13B |
| EBITDA | 11.53B |
| EBIT | 7.91B |
| Earnings Per Share (EPS) | 1,479.00 |
Balance Sheet
The company has 93.06 billion in cash and 425.38 million in debt, with a net cash position of 92.64 billion or 13,535.60 per share.
| Cash & Cash Equivalents | 93.06B |
| Total Debt | 425.38M |
| Net Cash | 92.64B |
| Net Cash Per Share | 13,535.60 |
| Equity (Book Value) | 131.64B |
| Book Value Per Share | 19,210.93 |
| Working Capital | 98.85B |
Cash Flow
In the last 12 months, operating cash flow was 11.11 billion and capital expenditures -3.10 billion, giving a free cash flow of 8.00 billion.
| Operating Cash Flow | 11.11B |
| Capital Expenditures | -3.10B |
| Depreciation & Amortization | 3.61B |
| Net Borrowing | -612.73M |
| Free Cash Flow | 8.00B |
| FCF Per Share | 1,169.58 |
Margins
Gross margin is 72.20%, with operating and profit margins of 14.90% and 19.06%.
| Gross Margin | 72.20% |
| Operating Margin | 14.90% |
| Pretax Margin | 21.18% |
| Profit Margin | 19.06% |
| EBITDA Margin | 21.70% |
| EBIT Margin | 14.90% |
| FCF Margin | 15.07% |
Dividends & Yields
This stock pays an annual dividend of 450.00, which amounts to a dividend yield of 3.13%.
| Dividend Per Share | 450.00 |
| Dividend Yield | 3.13% |
| Dividend Growth (YoY) | 33.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 30.42% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 3.20% |
| Earnings Yield | 10.45% |
| FCF Yield | 8.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cell Biotech has an Altman Z-Score of 13.74 and a Piotroski F-Score of 6.
| Altman Z-Score | 13.74 |
| Piotroski F-Score | 6 |